Laboratorios Duncan – Miriam Martinez, CEO – Argentina
Miriam Martinez, CEO of Laboratorios Duncan and VP of CAPGEN, discusses the challenges her company faces as a generic manufacturer in a branded generic market and their plans for growth…
Bioceres is an Argentina-based firm that manages investments in agricultural biotechnology and related sciences. It was founded in December 2001 by 23 farmers and is now owned by more than 270 shareholders, most of them innovative farmers but also coops and different actors from the agro-industrial sector. Every year, Bioceres shareholders plant about 2.5 million hectares in different regions of Latin America.
Since its beginnings, Bioceres has been a bridge between the scientific community and the agricultural production sector, fostering public-private associations and the development of collaborative networks.
Bioceres is a firm open to new shareholders with a shared dream-developing new technologies that help us use natural resources in a more efficient way while increasing and stabilizing the productivity of ecosystems.
Bioceres goes from genes to seeds, linking the laboratory to the field, adding value in every stage, and building and strengthening public-private partnerships.
CONTACT DETAILS
Ocampo 210 bis, predio CCT Rosario, (2000) Rosario, Santa Fe, Argentina
Phone: (54) 341 486 1100 Fax:(54) 341 486 1100
Miriam Martinez, CEO of Laboratorios Duncan and VP of CAPGEN, discusses the challenges her company faces as a generic manufacturer in a branded generic market and their plans for growth…
KPMG’s lead healthcare consultant in Argentina gives an in-depth analysis of the long-term needs and objectives driving change in the industry, the structural issues that need to be overcome before…
The founder and president of Close Up International shares the story of the genesis, evolution, and growth of both his company and the prescription auditing industry, as well as his…
The executive director of Latin America’s largest plasma fractionation plant, a publicly-funded laboratory within the 400 year old National University of Cordoba, discusses the organization’s social responsibility as a provider and leader…
Over the course of a day of unprecedented collaboration, Argentina’s biotech industry came together to discuss the challenges facing their industry in Argentina and the region at BioArgentina 2014, an event…
Nicola Carusoni, PwC’s lead pharmaceutical partner in Buenos Aires, gives an overview of the key trends in the Argentinian pharma industry and discusses the importance of PwC as a partner to the…
Mauro Bono discusses the challenges of building a company from the interior of Argentina, and shares his assessment of the key issues driving and preventing change in the country’s pharmaceutical…
Glenmark’s country manager for Argentina discusses Argentina’s development expertise and how companies like Glenmark can capitalize on it through partnerships and collaborations. How did you become part of Glenmark,…
“We are glad to host, together with ETIF, an event bringing forward pharma technologies to Argentinian patients. We hope this collaboration with ETIF will be the first of many” – Ines…
President of the company, Alberto Alvarez-Saavedra, discusses the company’s transformation into a professional organization, and the strategy which has driven remarkable growth in recent years, and will continue to do so…
On behalf of the chamber of industry that represents research-based pharma and biopharma companies in Argentina, Ernesto Felicio discusses the current challenges facing the industry, and the chambers current agenda…
Long-term strategy is the name of the game for Janssen. Alejandro Smolje, the company’s director of finance for Latin America South, outlines how that strategy is implemented in Argentina and…
See our Cookie Privacy Policy Here
